

Selective Modulators of PPAR-gamma and Methods for the Use Thereof

Inventors:

Ron Evans and Barry Forman

Applications:

Cardiovascular, Obesity, Drug Discovery and Development

Use of PPAR-gamma-selective compounds for the treatment of obesity and diabetes.

Because obesity is associated with the development of serious medical conditions, including noninsulin-dependent diabetes mellitus, hypertension, coronary artery disease, hyperlipidemias and certain malignancies, it is important that compounds to control adiposity are identified. The conversion of fibroblasts into cells of the adipose lineage is induced by expression of the orphan nuclear receptor PPAR-gamma. Accordingly, an endogenous PPAR-gamma ligand may be an important regulator of adipogenesis. This invention reveals PPAR-gamma as a drug target and relates to a class of compounds which are capable of selectively modulating processes mediated by PPAR-gamma. The identification of such compounds makes possible the selective intervention in PPAR-gamma mediated pathways, without exerting inadvertent effects on pathways mediated by other PPAR isoforms.

References:

Cell 1995 Dec 1;83(5):803-12.

Patent Status:

U.S. Patent No. 6,022,897 issued February 8, 2000

U.S. Patent No. 6,830,882 issued December 14, 2004

License Terms:

Exclusive or Nonexclusive licenses available

Reference Number: S95031

Contact: Anne-Marie Mueller, Director, OTM, 858.453.4100 x1275, amueller@salk.edu